ET
ETON.US Eton Pharmaceuticals Inc
- Market cap
- USD 1.84B
- P/E
- 40.0x
- P/B
- 20.39x
- ROE
- 74.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ETON.US undervalued?
Graham numberThe Graham number of Eton Pharmaceuticals Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eton Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Eton Pharmaceuticals Inc yet.
Eton Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and…
Full company profileEton Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eton Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 959K | 39.0K | 21.8M | 21.3M | 31.6M | 39.0M | 80.0M | 160M |
| Gross Profit | -13.0K | -63.0K | 506K | -247K | 19.2M | 14.3M | 21.1M | 23.4M | 42.7M | 113M |
| Operating Income | -7.15M | -10.3M | -18.6M | -27.1M | -1.50M | -8.26M | -1.19M | -2.60M | 72.0K | 51.0M |
| EBITDA | -7.14M | -10.3M | -18.2M | -26.5M | -1.49M | -7.25M | 212K | -657K | 4.27M | 54.4M |
| Net Income | -7.16M | -12.7M | -18.3M | -28.0M | -1.96M | -9.02M | -936K | -3.82M | -4.60M | 64.5M |
| EPS | -0.41 | -1.99 | -1.03 | -1.33 | -0.08 | -0.36 | -0.04 | -0.15 | -0.17 | 1.94 |
| Balance Sheet | ||||||||||
| Total Assets | 13.4M | 28.3M | 17.1M | 26.3M | 27.5M | 25.0M | 31.7M | 76.1M | 92.1M | 157M |
| Total Liabilities | 1.31M | 2.02M | 6.52M | 10.7M | 9.84M | 12.0M | 16.3M | 51.7M | 66.0M | 70.4M |
| Shareholders' Equity | 12.1M | 26.3M | 10.6M | 15.7M | 17.6M | 13.1M | 15.5M | 24.4M | 26.2M | 86.9M |
| Cash & Short-term Investments | 13.2M | 26.7M | 12.1M | 21.3M | 14.4M | 16.3M | 21.4M | 14.9M | 25.9M | 55.6M |
| Total Debt | - | - | 4.67M | 7.14M | 6.70M | 6.52M | 5.40M | 30.0M | 31.0M | 24.1M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.72M | -8.15M | -18.0M | -22.3M | -4.72M | 4.82M | 6.82M | 969K | 10.5M | 66.5M |
| Capital Expenditure | 130K | 236K | 1.85M | 50.0K | 3.26M | 2.79M | 775K | 26.0K | 333K | 124K |
| Free Cash Flow | -4.85M | -8.38M | -19.9M | -22.4M | -7.98M | 2.03M | 6.04M | 943K | 10.2M | 66.4M |
| Ratios | ||||||||||
| ROE | -59.0% | -48.4% | -173.6% | -178.6% | -11.1% | -69.0% | -6.0% | -15.7% | -17.6% | 74.2% |
| ROA | -53.2% | -45.0% | -107.3% | -106.3% | -7.1% | -36.0% | -2.9% | -5.0% | -5.0% | 41.0% |
| Net Profit Margin | - | - | -1,910.3% | -71,717.9% | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% | 40.4% |
| Debt to Equity | - | - | 0.44x | 0.46x | 0.38x | 0.50x | 0.35x | 1.23x | 1.19x | 0.28x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eton Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 1.05M | 0.16 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Eton Pharmaceuticals Inc
- Insiders 4.85%
- Institutions 73.90%
- Public & others 21.26%
- Shares outstanding 28.8M
- Free float 22.8M
Top funds holding ETON.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 869K | 3.02% | +24.74% | Sep 2026 |
| iShares Russell 2000 ETF | 672K | 2.33% | 0.00% | Oct 2026 |
| Oberweis Micro-Cap | 484K | 1.68% | +14.97% | Jun 2026 |
| Fidelity Small Cap Growth | 439K | 1.52% | +73.60% | Aug 2026 |
| Fidelity Small Cap Index | 292K | 1.01% | +0.15% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 251K | 0.87% | -0.38% | Oct 2026 |
| Fidelity Small Cap Growth K6 | 230K | 0.80% | +74.11% | Aug 2026 |
| Nuveen Quant Small Cap Equity R6 | 226K | 0.78% | -10.81% | Aug 2026 |
| Janus Henderson Venture D | 191K | 0.66% | 0.00% | Sep 2026 |
| First Trust Small Cap Gr AlphaDEX® ETF | 167K | 0.58% | +0.43% | Oct 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 157K | 0.55% | +2.88% | Oct 2026 |
| Wasatch Micro Cap | 156K | 0.54% | +70.16% | Sep 2026 |
| Vanguard Russell 2000 ETF | 155K | 0.54% | +1.12% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 144K | 0.50% | +0.22% | Oct 2026 |
| Fidelity Extended Market Index | 124K | 0.43% | +8.94% | Sep 2026 |
| Rockefeller US Sm Cp Eq Impr F USDAccUnh | 115K | 0.40% | +1.84% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 112K | 0.39% | 0.00% | Sep 2026 |
| First Trust Small Cap Core AlphaDEX® ETF | 82.0K | 0.28% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 81.0K | 0.28% | 0.00% | Oct 2026 |
| Fidelity® SAI Small-Mid Cap Momt Idx | 69.7K | 0.24% | -3.93% | Sep 2026 |
Top institutions holding ETON.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Opaleye Management Inc | 2.86M | 9.92% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 2.35M | 8.16% | +100.00% | Jun 2026 |
| EcoR1 Capital, LLC | 2.17M | 7.53% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.90M | 6.58% | +10.40% | Jun 2026 |
| Vanguard Capital Management, LLC | 977K | 3.39% | -1.76% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 768K | 2.66% | +60.68% | Jun 2026 |
| State Street Corp | 702K | 2.43% | +32.36% | Jun 2026 |
| Geode Capital Management, LLC | 652K | 2.26% | +12.92% | Jun 2026 |
| Oberweis Asset Management Inc | 502K | 1.74% | +14.18% | Jun 2026 |
| National Philanthropic Trust | 492K | 1.71% | 0.00% | Jun 2026 |
| Westside Investment Management, Inc. | 431K | 1.50% | -7.86% | Jun 2026 |
| Pillsbury Lake Capital LLC | 387K | 1.34% | +6.08% | Jun 2026 |
| Nuveen, LLC | 376K | 1.30% | +548.33% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 322K | 1.12% | +6.74% | Jun 2026 |
| Woodline Partners LP | 311K | 1.08% | +82.12% | Jun 2026 |
| Northern Trust Corp | 256K | 0.89% | +7.58% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 249K | 0.86% | +201.23% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 213K | 0.74% | +401.10% | Sep 2026 |
| Thompson, Siegel & Walmsley LLC | 211K | 0.73% | -28.86% | Sep 2026 |
| Panoramic Capital, LLC | 208K | 0.72% | +12.54% | Jun 2026 |
Eton Pharmaceuticals Inc company profile
- Company name
- Eton Pharmaceuticals Inc
- Ticker
- ETON.US
- Exchange
- USA Stocks
- Listed since
- Nov 13, 2018
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 44
- Fiscal year end
- December
- Address
- 21925 W. Field Parkway, Deer Park, IL, United States, 60010-7278
- Phone
- 847 787 7361
- Website
- etonpharma.com
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals Inc management
7- Mr. Sean E. BrynjelsenPresident, CEO & Director · born 1972
- Mr. David C. KrempaChief Business Officer · born 1989
- Mr. James R. Gruber CPAConsultant · born 1972
- Ms. Ipek Erdogan-TrinkausChief Commercial Officer · born 1982
- Ms. Judith M. MatthewsChief Financial Officer & Secretary · born 1970
- Ms. Danka RadosavljevicChief Operating Officer · born 1984
- Mr. Scott GrossenbachSenior Vice President of Sales Operations